TCGA-60-2708-01A-01R-0851-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 64
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.670
- ANGIOGENESIS+0.540
- HEDGEHOG_SIGNALING+0.510
- HYPOXIA+0.470
- NOTCH_SIGNALING+0.380
- APICAL_JUNCTION+0.370
- GLYCOLYSIS+0.320
- MYC_TARGETS_V1+0.320
- WNT_BETA_CATENIN_SIGNALING+0.320
- PANCREAS_BETA_CELLS+0.310
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.620
- INTERFERON_GAMMA_RESPONSE-0.450
- ALLOGRAFT_REJECTION-0.370
- OXIDATIVE_PHOSPHORYLATION-0.190
- BILE_ACID_METABOLISM-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.140
- COMPLEMENT-0.120
- HEME_METABOLISM-0.110
- IL6_JAK_STAT3_SIGNALING-0.090
- FATTY_ACID_METABOLISM-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.860 |
| 2 | SRR8943050 | — | — | 0.823 |
| 3 | 20020076.Her2HRpos | — | C | 0.821 |
| 4 | SRR2932813 | — | — | 0.818 |
| 5 | C3L-02168 | — | cohortSQ2 | 0.816 |
| 6 | TCGA-AN-A04A-01A-21R-A034-07 | — | C | 0.813 |
| 7 | MBCProject_6109_T1A_RNA | — | C | 0.801 |
| 8 | TCGA-CR-5247-01A-01R-2016-07 | — | — | 0.795 |
| 9 | TCGA-34-5236-01A-21R-1820-07 | — | cohortSQ1 | 0.793 |
| 10 | SRR5903555 | — | cohortSQ1 | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.670 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.540 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.510 | Inavolisib | — uncovered |
| HYPOXIA | 0.470 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |